Skip to content

Trial Summary

This is a phase 2, open-label, single-arm, multicenter clinical trial designed to evaluate the efficacy and safety of talimogene laherparepvec in combination with pembrolizumab following disease progression on prior anti-PD-1 therapy in unresectable/metastatic melanoma stage IIIB-IVM1d) or prior anti-PD-1 therapy in the adjuvant setting.

Acronym:

MASTERKEY-115

ACTRN/NCT /ethics:

NCT04068181

Scientific title:

Phase 2 Study of Talimogene Laherparepvec in Combination With Pembrolizumab in Subjects With Unresectable/Metastatic Stage IIIB-IVM1d Melanoma Who Have Progressed on Prior Anti PD-1 Based Therapy

Sponsor / Cooperative group:

Amgen

Trial & Patient Characteristics

Cancer TypeMelanoma & other skin
Trial TypeTreatment
PhasePhase II
Age Range18 years and older
SexBoth
Tumour Stream -
Cancer StageMetastatic or Widespread
Anticipated Start Date2020-01-27
Anticipated End Date2023-10-24

Participating Hospitals

HospitalThe Queen Elizabeth Hospital
Clinical Trial CoordinatorPamela Cooper
Emailpamela.cooper@sa.gov.au
Phone08 8222 6140
Principal InvestigatorDr Rachel Roberts-Thomson
Recruitment StatusRecruiting